Celltrion unveils phase 1 clinical data of Actemra biosimilar in Europe

CT-P47 successfully demonstrates pharmacodynamic equivalence and safety comparable to the original drug

Celltrion unveils phase 1 clinical data of Actemra biosimilar in Europe
Yoo-Rim Kim 1
2023-05-31 17:43:55 youforest@hankyung.com
Bio & Pharma


South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, at the 2023 European Congress of Rheumatology (2023 EULAR) conference.

Actemra, a subcutaneous injection (SC) formulation developed by Roche, generated sales worth $3.4 billion last year. EULAR, recognized as the world's most prestigious rheumatology society, commenced its annual conference in Milan, Italy, on the same day and will continue until June 3.

The clinical data for CT-P47 was made available online by Celltrion, following a phase 1 study involving 318 health South Korean subjects. The company announced that it had successfully demonstrated pharmacodynamic (PK) equivalence and safety comparable to the original drug.

CT-P47 is indicated for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis and cytokine release syndrome.

In addition to the subcutaneous injection formulation, Celltrion is developing CT-P47 in an intravenous injection (IV) formulation to offer flexibility to medical professionals when prescribing the treatment, based on patient conditions and convenience. The IV formulation has been undergoing global phase 3 trials since July of last year.

Actemra, a biopharmaceutical designed to inhibit the interleukin-6 protein responsible for inflammation in the body, has already expired its substance patent, though the formulation patent remains valid for a period of time. The launch of Actemra biosimilar CT-P47 is scheduled for the second half of next year.

Celltrion anticipates that the introduction of CT-P47 will further strengthen its product portfolio, distinguishing itself from other autoimmune disease biosimilars such as Remsima currently available in the market.

Remsima, a tumor necrosis factor (TNF-α) inhibitor, stands in contrast to CT-P47, which functions as an interleukin inhibitor.

Write to Yoo-Rim Kim at youforest@hankyung.com
#Celltrion #Actemra #biosimilar #CT-P47 #phase 1 clinical data #Europe #2023 European Congress of Rheumatology

Celltrion gets FDA approval for Humira biosimilar CT-P17

Celltrion gets FDA approval for Humira biosimilar CT-P17

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Administration for its biosimilar of the autoimmune disease treatment drug Humira (adalimumab) called CT-P17 (brand name: Yuflyma).As a result, Celltrion

Celltrion drops bid to acquire Baxter’s biopharm unit

Celltrion drops bid to acquire Baxter’s biopharm unit

Celltrion Inc. announced on Tuesday it has decided not to pursue the acquisition of the biopharmaceutical unit of U.S. medical device maker Baxter International Inc.In March, Reuters reported that Celltrion, South Korea’s largest biosimilar maker, and several U.S. companies are competing

Celltrion applies for Phase 3 clinical trials in Europe for biosimilar

Celltrion applies for Phase 3 clinical trials in Europe for biosimilar

South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ingredient ocrelizumab).The company on Tuesday said it submitted an investigational new drug application for Phase 3 clinical trials for the Ocrev

S.Korea's Celltrion Healthcare launches Vegzelma in US

S.Korea's Celltrion Healthcare launches Vegzelma in US

South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorectal and breast cancer sold under the name Avastin.The company has prepared for the launch since September last year, when it received approval to se

Biosimilar giant Celltrion to transform into drug developer

Biosimilar giant Celltrion to transform into drug developer

Celltrion’s founder Seo Jung-jin speaks to the press at an online conference on March 29, 2023 (Courtesy of Celltrion) South Korean biosimilar giant Celltrion Group aims to transform into a drug developer by generating 40% of sales from new medicines by 2030 as it is scheduled to work on

(* comment hide *}